Literatur "Pharmako-logisch! – Demenz"

[1] Brunden KR, Trojanowski JQ, Lee VM. Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies. Nat Rev Drug Discov 2009;8:783-93.

[2] Conforti L, Adalbert R, Coleman MP. Neuronal death: where does the end begin? Trends Neurosci 2007;30:159-66.

[3] DeKosky ST et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA 2008;300:2253-63.

[4] Doody RS, Gavrilova SI, Sano M, Thomas RG, Aisen PS, Bachurin SO, Seely L, Hung D. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet 2008;372:207-15.

[5] Dong H, Csernansky JG. Effects of stress and stress hormones on amyloid-beta protein and plaque deposition. J Alzheimers Dis 2009;18:459-69.

[6] DeKosky ST et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA 2008; 300:2253-63.

[7] de la Monte SM. Insulin resistance and Alzheimer's disease. BMB Rep 2009;42:475-81.

[8] Evin G, Barakat A, Masters CL. BACE: Therapeutic target and potential biomarker for Alzheimer's disease. Int J Biochem Cell Biol 2010.

[9] Grinberg LT, Thal DR. Vascular pathology in the aged human brain. Acta Neuropathol 2010;119:277-290.

[10] Jones RW. Demibon disappointment. Alzheimers Res Ther. 2010;2:25.

[11] Kloft A, Kellermann C. Blutungsneigung durch Ginkgo-biloba-Extrakt? Pharmazie in unserer Zeit 2009;5:440

[12] Knopman DS, Roberts R. Vascular risk factors: imaging and neuropathologic correlates. J Alzheimers Dis 2010;20:699-709.

[13] Kokjohn TA, Roher AE. Antibody responses, amyloid-beta peptide remnants and clinical effects of AN-1792 immunization in patients with AD in an interrupted trial. CNS Neurol Disord Drug Targets 2009;8:88-97.

[14] Koller L, Knebel M, Kaiser E, Schroder J. Leichte kognitive Beeintrachtigung, demenzielle und depressive Erkrankungen. Klinikarzt 2010;39:240-4.

[15] Ley L, Herdegen T. Neuroprotektion als Nebenwirkung – therapeutische Arzneimittelwirkungen am Nervensystem. Arzneimitteltherapie 2004;22: 6-19.

[16] Mahlberg R, Gutzmann H. Diagnostik von Demenzerkrankungen. Dt Arztebl 2005;102:1621-7.

[17] Medical Research Council Cognitive Function and Aging Study. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. (MRC CFAS). Lancet. 2001;357:169-75.

[18] Metcalfe MJ, Figueiredo-Pereira ME. Relationship between tau pathology and neuroinflammation in Alzheimer's disease. Mt Sinai J Med 2010;77:50-8.

[19] Mistur R, Mosconi L, Santi SD, Guzman M, Li Y, Tsui W, de Leon MJ. Current Challenges for the Early Detection of Alzheimer's Disease: Brain Imaging and CSF Studies. J Clin Neurol 2009;5:153-66.

[20] Murphy MP, LeVine H. Alzheimer's Disease and the Amyloid-beta Peptide. J Alzheimers Dis 2010;19:311-23.

[21] Rabinovici GD, Jagust WJ. Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo. Behav Neurol 2009;21:117-28.

[22] Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ. A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch Neurol 2006;63:49-54.

[23] Reitz C, Mayeux R. Use of genetic variation as biomarkers for mild cognitive impairment and progression of mild cognitive impairment to dementia. J Alzheimers Dis 2010;19:229-51.

[24] Rosenberg PB, Hillis AE. Biomarkers for Alzheimer’s disease: ready for the next step. Brain 2009;132:2002-4.

[25] Schwalbe O, Wunderlich S, Kloft C. Pharmakotherapie einer Patientin mit Alzheimer-Demenz. Interaktionen mit dem Antidementivum Galantamin. MMP 2006;29:222-4.

[26] Smith AD, Smith SM, de Jager CA, Whitbread P, Johnston C, Agacinski G et al. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. PLoS One. 2010; 5:e12244

[27] Smith MA, Zhu X, Tabaton M, Liu G, McKeel DW Jr, Cohen ML et al. Increased iron and free radical generation in preclinical Alzheimer disease and mild cognitive impairment. J Alzheimers Dis 2010;19:363-72.

[28] Tarawneh R, Holtzman DM. Critical issues for successful immunotherapy in Alzheimer's disease: development of biomarkers and methods for early detection and intervention. CNS Neurol Disord Drug Targets 2009;8:144-59.

[29] Ude C et al. Chemie, Pharmakokinetik und Metabolismus von Ginkgo-Extrakt. Pharmazie in unserer Zeit 2009;5:418

[30] Vandenberghe R, Tournoy J. Cognitive aging and Alzheimer’s disease. Postgrad Med J. 2005;81:343-52.

[31] Wolter DK, Risiken von Antipsychotika im Alter, speziell bei Demenz. Psychopharmakotherapie 2010;17:27-36.

[32] Yaffe K, Krueger K, Cummings SR et al. Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. Am J Psychiatry 2005;162:683-90.

Zurück zum Inhaltsverzeichnis "Pharmako-logisch! – Demenz"